Lumos Pharma Revenue vs. Operating Margin
| LUMO Stock | USD 4.30 0.02 0.46% |
For Lumos Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Lumos Pharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Lumos Pharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Lumos Pharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Lumos Pharma over time as well as its relative position and ranking within its peers.
Lumos |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lumos Pharma. If investors know Lumos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lumos Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Lumos Pharma is measured differently than its book value, which is the value of Lumos that is recorded on the company's balance sheet. Investors also form their own opinion of Lumos Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lumos Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lumos Pharma's market value can be influenced by many factors that don't directly affect Lumos Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lumos Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lumos Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lumos Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Lumos Pharma Operating Margin vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Lumos Pharma's current stock value. Our valuation model uses many indicators to compare Lumos Pharma value to that of its competitors to determine the firm's financial worth. Lumos Pharma is rated third overall in revenue category among its peers. It also is rated third overall in operating margin category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Lumos Pharma's earnings, one of the primary drivers of an investment's value.Lumos Revenue vs. Competition
Lumos Pharma is rated third overall in revenue category among its peers. Market size based on revenue of Health Care industry is now estimated at about 56.17 Million. Lumos Pharma holds roughly 2.05 Million in revenue claiming about 4% of equities under Health Care industry.
Lumos Operating Margin vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Lumos Pharma |
| = | 2.05 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Lumos Pharma |
| = | (10.52) % |
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Lumos Operating Margin Comparison
Lumos Pharma is currently under evaluation in operating margin category among its peers.
Lumos Pharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Lumos Pharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Lumos Pharma will eventually generate negative long term returns. The profitability progress is the general direction of Lumos Pharma's change in net profit over the period of time. It can combine multiple indicators of Lumos Pharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. Lumos Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 32 people.
Lumos Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Lumos Pharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Lumos Pharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Lumos Pharma's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Lumos Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Pattern Recognition Now
Pattern RecognitionUse different Pattern Recognition models to time the market across multiple global exchanges |
| All Next | Launch Module |
Use Investing Themes to Complement your Lumos Pharma position
In addition to having Lumos Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Casinos Thematic Idea Now
Casinos
Companies that are related to providing casino-type services across multiple geographical areas. The Casinos theme has 51 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Casinos Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Correlation Analysis. To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
To fully project Lumos Pharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Lumos Pharma at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Lumos Pharma's income statement, its balance sheet, and the statement of cash flows.